Figure 6
Survival analysis in MPN-blast phase. (A) Survival from the time of diagnosis of blast phase in transformed MPN patients with normal chromosome 7 (normal 7q) compared with either monosomy 7 (−7)/deletion of 7q (7q−) or 7qCNN-LOH. (B) Survival from the time of diagnosis of blast phase in transformed MPN patients with homozygous JAK2V617F+ associated with 9pCNN-LOH compared with either heterozygous JAK2V617F+ with 9p duplication/trisomy 9 or no abnormality, or patients without the mutation (JAK2 wild type). Median survival (months) and the case numbers for each group (transformed PV, ET, or PMF) are listed in supplemental Table 5.

Survival analysis in MPN-blast phase. (A) Survival from the time of diagnosis of blast phase in transformed MPN patients with normal chromosome 7 (normal 7q) compared with either monosomy 7 (−7)/deletion of 7q (7q−) or 7qCNN-LOH. (B) Survival from the time of diagnosis of blast phase in transformed MPN patients with homozygous JAK2V617F+ associated with 9pCNN-LOH compared with either heterozygous JAK2V617F+ with 9p duplication/trisomy 9 or no abnormality, or patients without the mutation (JAK2 wild type). Median survival (months) and the case numbers for each group (transformed PV, ET, or PMF) are listed in supplemental Table 5.

Close Modal

or Create an Account

Close Modal
Close Modal